Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; and.
Aalborg University Hospital, Universitetshospital, Aalborg, Denmark.
J Nucl Med. 2021 Sep 1;62(9):1252-1257. doi: 10.2967/jnumed.120.257741. Epub 2021 Feb 5.
Renal excretion of some prostate-specific membrane antigen (PSMA) ligands and consequently increased bladder activity can obscure locally relapsing prostate cancer lesions in PSMA PET/CT. Furthermore, additional late imaging in PSMA PET/CT provides a useful method to clarify uncertain findings. The aim of this retrospective study was to investigate a modified imaging protocol combining late additional imaging with hydration and forced diuresis in individuals undergoing additional late scanning for uncertain lesions or low prostate-specific antigen. We compared an older protocol with a newer one. In the old protocol, patients undergoing Ga-PSMA-11 PET/CT were examined at 90 min after injection, with 1 L of oral hydration beginning at 30 min after injection and 20 mg of furosemide given intravenously at 1 h after injection, followed by additional late imaging at 2.5 h after injection without further preparation. In the new protocol, a second group received the same procedure as before, with an additional 0.5 L of oral hydration and 10 mg of furosemide intravenously 30 min before the late imaging. We examined 132 patients (76 with the old protocol and 56 with the new one) with respect to urinary bladder activity (SUV), prostate cancer lesion uptake (SUV), and lesion contrast (ratio of tumor SUV to bladder SUV for local relapses and ratio of tumor SUV to gluteal-muscle SUV for nonlocal prostate cancer lesions). Bladder activity was significantly greater for the old protocol in the late scans than for the new protocol (ratio of bladder activity at 2.5 h to bladder activity at 1.5 h, 2.33 ± 1.17 vs. 1.37 ± 0.50, < 0.0001). Increased tumor SUV and contrast were seen at 2.5 h compared with 1.5 h ( < 0.0001 for old protocol; = 0.02 for new protocol). Increased bladder activity for the old protocol resulted in decreased lesion-to-bladder contrast, which was not the case for the new protocol. Tumor-to-background ratios increased at late imaging for both protocols, but the increase was significantly lower for the new protocol. For the old protocol, comparing the 1.5-h to the 2.5-h acquisitions, 4 lesions in 4 patients (4/76 = 5.2% of the cohort) were visible at the postdiuresis 1.5-h acquisition but not at 2.5 h, having been obscured as a result of the higher bladder activity. In the new protocol, 2 of 56 (3.6%) patients had lesions visible only at late imaging, and 2 patients had lesions that could be better discriminated at late imaging. Although the combination of diuretics and hydration can be a useful method to increase the visualization and detectability of locally recurrent prostate cancer in standard Ga-PSMA-11 PET/CT, their effects do not sufficiently continue into additional late imaging. Additional diuresis and hydration are recommended to improve the visibility, detection, and diagnostic certainty of local recurrences.
前列腺特异性膜抗原(PSMA)配体的肾脏排泄,以及随之而来的膀胱活动增加,可能会使 PSMA PET/CT 中局部复发性前列腺癌病灶变得模糊。此外,PSMA PET/CT 中的额外晚期成像提供了一种有用的方法来澄清不确定的发现。本回顾性研究的目的是调查一种改良的成像方案,该方案将晚期额外成像与水化和强制利尿相结合,用于对不确定的病灶或低前列腺特异性抗原进行额外的晚期扫描。我们比较了旧方案和新方案。在旧方案中,接受 Ga-PSMA-11 PET/CT 检查的患者在注射后 90 分钟进行检查,在注射后 30 分钟开始口服 1 升水,并在注射后 1 小时静脉注射 20 毫克呋塞米,然后在注射后 2.5 小时进行额外的晚期成像,无需进一步准备。在新方案中,第二组患者接受与之前相同的程序,在晚期成像前 30 分钟额外口服 0.5 升水和静脉注射 10 毫克呋塞米。我们检查了 132 名患者(旧方案 76 名,新方案 56 名)的膀胱活动(SUV)、前列腺癌病灶摄取(SUV)和病灶对比度(局部复发肿瘤 SUV 与膀胱 SUV 的比值和非局部前列腺癌病灶肿瘤 SUV 与臀肌 SUV 的比值)。在晚期扫描中,旧方案的膀胱活动明显高于新方案(2.5 小时与 1.5 小时膀胱活动的比值,2.33 ± 1.17 与 1.37 ± 0.50, < 0.0001)。与 1.5 小时相比,2.5 小时的肿瘤 SUV 和对比度增加(旧方案 < 0.0001;新方案 = 0.02)。旧方案中较高的膀胱活动导致病灶与膀胱的对比度降低,而新方案则不是这种情况。两种方案的肿瘤与背景比值在晚期成像时均增加,但新方案的增加幅度明显较低。对于旧方案,将 1.5 小时与 2.5 小时的采集进行比较,在 4 名患者(4/76,队列的 5.2%)的 4 个病灶在利尿后 1.5 小时的采集时可见,但在 2.5 小时时不可见,由于膀胱活动较高而被掩盖。在新方案中,56 名患者中有 2 名(3.6%)仅在晚期成像时可见病灶,有 2 名患者在晚期成像时可以更好地区分病灶。尽管利尿剂和水化的联合使用可以是一种有用的方法,可增加标准 Ga-PSMA-11 PET/CT 中局部复发性前列腺癌的可视化和可检测性,但它们的效果在晚期成像中不能充分持续。建议额外使用利尿剂和水化来提高局部复发的可见性、检测和诊断确定性。